Lilly buys Ventyx Biosciences for $1.2 billion

Eli Lilly said on Jan. 7 it will acquire Ventyx Biosciences, a San Diego biotech working on oral anti-inflammatory drugs, for $14 a share in cash, a deal valued at about $1.2 billion.^[1][3] The purchase is Lilly's first major deal of 2026 and comes after a year in which the company's market value passed $1 trillion, driven by sales of its GLP-1 drugs Mounjaro and Zepbound.^[1]

Ventyx's lead drug, VTX3232, blocks a protein complex called NLRP3 that drives inflammation in the body. In October, Ventyx reported that the drug cut a biomarker of heart disease risk by 64% over 12 weeks, compared with a 3% rise in patients who got a placebo.^[2] When paired with semaglutide, the active ingredient in Novo Nordisk's Wegovy, the combination also lowered markers of liver inflammation and other cardiovascular signs.^[2] VTX3232 has also completed a Phase 2 biomarker study in early-stage Parkinson's disease.^[3] A second Ventyx drug, VTX2735, is in Phase 2 testing for recurrent pericarditis, an inflammation of the tissue around the heart.^[3] The company's pipeline also includes two Phase 2 drugs for inflammatory bowel diseases such as Crohn's and ulcerative colitis: tamuzimod and VTX958.^[1][3]

Sources describe the deal's premium differently. Reuters put it at about 2% over Ventyx's stock price the day before the deal was announced, after shares had already jumped 28% on reports of talks.^[1] BioPharma Dive and Lilly's own release calculate the premium differently, saying the $14 price is 62% above Ventyx's 30-day average trading price through Jan. 5.^[2][3] The deal does not depend on financing and is expected to close in the first half of 2026, pending Ventyx shareholder and regulatory approval.^[1][3]

Lilly executives framed the purchase as part of a broader bet on inflammation as a driver of chronic disease. "There is increasing evidence that inflammation is a key driver of many chronic diseases," said Daniel Skovronsky, Lilly's chief scientific and product officer, adding that Ventyx's pipeline "strengthens our ability to deliver meaningful advances" in cardiometabolic health, neurodegeneration and autoimmunity.^[2][3] Analysts noted the price tag is modest for Lilly. Cantor Fitzgerald's Carter Gould called the $1.2 billion "borderline immaterial" to the company and said the program fits well within Lilly's cardiometabolic business.^[1] Stifel's Alex Thompson said the deal validates NLRP3 as a drug target, noting at least 17 competing programs exist, and that Lilly "has the resources to fully interrogate the breadth of indications."^[2]

Why it matters for patients

This deal does not change anything about currently available GLP-1 drugs like Ozempic, Wegovy, Mounjaro or Zepbound. No new obesity or diabetes drug is involved. Instead, it shows Lilly using profits from its metabolic drug franchise to build out treatments for a different set of conditions, including inflammatory bowel disease, pericarditis and Parkinson's disease.^[1][2][3] For patients on GLP-1 therapies today, the more notable detail may be the early data showing VTX3232 combined with semaglutide reduced liver inflammation markers, since Ventyx and Lilly may explore whether inflammation-targeting drugs could complement metabolic treatments in the future.^[2] That research is still in mid-stage trials, and it is not yet known whether or when any combination product would reach patients.

What happens next

The acquisition is expected to close in the first half of 2026, subject to a vote by Ventyx shareholders and regulatory clearance.^[1][3] Lilly has not detailed a timeline for advancing Ventyx's drugs through further trials once the deal closes.